Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 04/27/17

Naoko Takebe, MD, PhD

Naoko Takebe, MD, PhD

Medical Officer

Dr. Takebe joined CTEP in September 2007 as a Senior Investigator at the Investigational Drug Branch. Her current portfolio includes agents causing programmed cell death, cancer stem cell targeting agents, DNA damaging repair inhibitors, and a Src inhibitor. Dr. Takebe received her M.D. and Ph.D. degrees from Hirosaki University, Japan. She completed her medical Hematology/Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in 1997, and a Postdoctoral Research Fellowship at the Memorial Sloan-Kettering Institute in 1999. Her research at that time focused on experimental therapeutics including gene therapy approach using retroviral gene transfer to deliver drug resistance genes into hematopoietic stem cells for myeloprotection. In 1999, she joined the Blood and Stem Cell Transplant Program in the Department of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland. There she conducted clinical trials in the area of multiple myeloma and leukemia involving autologous and allogeneic transplants. Her laboratory research centered on experimental therapeutics in order to develop novel anti-cancer agents, developing new animal models for leukemia, and to explore novel umbilical cord blood stem cell ex vivo expansion approaches. Currently, she is a translational science PI for the Exceptional Responder Initiative protocol, and a NCI co-investigator for NCI-MATCH and Pediatric MATCH under NCI Precision Medicine Initiatives. She serves as an Associate editor for Current Problems in Cancer from Elsevier. She also is a member of NCI Provocative Question team. She serves as an oversea member for the Immunotherapy Guidance Working Group in Japan. She is board certified in Hematology and Medical Oncology.

National Cancer Institute
9609 Medical Center Drive 5W-450 Rockville MD 20850
Phone: 240-276-6121

About the Branch Chief

Jeffrey A. Moscow, MD Jeffrey A. Moscow, MD, joined the Investigational Drug Branch (IDB) in January 2014 after serving part time since August 2012. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. More…